Bajaj Healthcare gave three different timelines for its peptide plant on the same call
Management said the facility would commission by Q4 2027, then later said commercialize in Q4 of this year, then reverted to Q4 2027 — leaving investors unsure when Semaglutide revenue will actually flow.
What's new
- Q1 FY27 revenue ₹166 cr (+11.3% YoY), EBITDA margin 17.8% (+110 bps QoQ)
- Domestic API grew 27% YoY to ₹92.3 cr, volume-led with stable prices
- Peptide pipeline includes 4 developed molecules, Semaglutide as first production target
- Management guided for ₹900-1,000 cr revenue in 2-3 years
Themes from the call
Demand
Domestic API volume rose 27% YoY; formulations focused on higher-margin branded products
Margins
Gross margin up 210 bps to 48.3%; EBITDA margin guided 18-20% for FY27-28
Capital allocation
Debt-equity improved to 0.5; annual capex ₹40-50 cr; deleveraging continuing
Guidance watch
- FY27 revenue growth 10-15% and similar for FY28; EBITDA margin 18-20%
- Peptide plant at full utilization could generate ₹200-300 cr revenue at 18-20% margin
- Cenobamate launch of ₹10-12 cr in FY27 pending approvals
- Exports targeted at 30-35% of revenue in near term
Risk flags
- Peptide facility timeline inconsistency — multiple conflicting statements on commercialization
- Working capital: receivable days at 131, inventory high due to precautionary ordering
- Approvals pending for Cenobamate, Suvorexant, Genex Nashik
Key quotes
-
"Over the next 2-3 years, you can expect revenue around Rs 900-1,000 crore."
— Anil Jain, Managing Director -
"Our plant is going to commercialize in Q4 of this year. The first production would be Semaglutide."
— Management, later in call -
"The commercialization will be in the last quarter of 2027, as I mentioned."
— Management, same call
The brief
Bajaj Healthcare's Q1 numbers were solid: revenue up 11%, gross margin up 210 bps, domestic API growing 27%. The story is about the pipeline (peptides, oncology, branded formulations) and the company's deliberate shift from bulk to high-value products. The ambition is clear: ₹900-1,000 crore revenue in 2-3 years, with the peptide plant alone capable of ₹200-300 crore at 18-20% margins. But the call contained a confusing, unresolved contradiction about the peptide plant timeline. Management first said commissioning by Q4 2027, then said commercialization in Q4 of this year, then reverted to Q4 2027, all in the same call. No explanation was given. That makes it hard to take the guidance at face value. If the facility is on track, the stock has a multibagger story. If the timeline slips, the revenue target becomes a hope. Investors deserve a clear answer. Until then, the peptide inflection remains a promise without a schedule.
Bajaj Healthcare's peptide bet has big upside if the timeline holds, but the call's contradictions make it hard to rely on.